[1] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.   doi: 10.3322/caac.21590
[2] Zheng RS, Zhang SW, Zeng HM, et al.  Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.   doi: 10.1016/j.jncc.2022.02.002
[3] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[4] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
Chinese Society of Nuclear Medicine.  Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
[5] Klain M, Nappi C, Zampella E, et al.  Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4437-4444.   doi: 10.1007/s00259-021-05440-x
[6] Wei L, Zhao GG, Lv NN, et al.  Negative remnant 99mTc-pertechnetate uptake predicts excellent response to radioactive iodine therapy in low- to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy[J]. Ann Nucl Med, 2019, 33(2): 112-118.   doi: 10.1007/s12149-018-1314-4
[7]

Giannoula E, Melidis C, Papadopoulos N, et al. Dynamic risk stratification for predicting treatment response in differentiated thyroid cancer[J/OL]. J Clin Med, 2020, 9(9): 2708[2021-03-03]. https://www.mdpi.com/2077-0383/9/9/2708. DOI: 10.3390/jcm9092708.
[8]

Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8th ed. Cham: Springer, 2017.
[9] 周倩, 王瑞华, 刘保平, 等.  高危分化型甲状腺癌手术及131I治疗后疗效分类及影响因素分析[J]. 中华核医学与分子影像杂志, 2021, 41(11): 664-669.   doi: 10.3760/cma.j.cn321828-20200812-00310
Zhou Q, Wang RH, Liu BP, et al.  Classification of therapeutic effect and influencing factors in patients with high-risk differentiated thyroid carcinoma after surgery and 131I treatment[J]. Chin J Nucl Med Mol Imaging, 2021, 41(11): 664-669.   doi: 10.3760/cma.j.cn321828-20200812-00310
[10] Giovanella L, Paone G, Ruberto T, et al.  99mTc-pertechnetate scintigraphy predicts successful postoperative ablation in differentiated thyroid carcinoma patients treated with low radioiodine activities[J]. Endocrinol Metab (Seoul), 2019, 34(1): 63-69.   doi: 10.3803/EnM.2019.34.1.63
[11] Giovanella L, Suriano S, Ricci R, et al.  Postsurgical thyroid remnant estimation by 99mTc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma[J]. Head Neck, 2011, 33(4): 552-556.   doi: 10.1002/hed.21490
[12] Shangguan LJ, Fang SW, Zhang PP, et al.  Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy[J]. Ann Nucl Med, 2019, 33(3): 177-183.   doi: 10.1007/s12149-018-01321-w
[13]

Xiao L, Zhang WJ, Wang YQ, et al. Prognostic value of star-shaped intense uptake of 131I in thyroid cancer patients[J/OL]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2021, 40(1): 30−36[2021-03-03]. https://www.sciencedirect.com/science/article/abs/pii/S2253654X20300317?via%3Dihub. DOI: 10.1016/j.remn.2020.03.002.
[14] Kong SH, Lim JA, Song YS, et al.  Star-shaped intense uptake of 131I on whole body scans can reflect good therapeutic effects of low-dose radioactive iodine treatment of 1.1 GBq[J]. Endocrinol Metab (Seoul), 2018, 33(2): 228-235.   doi: 10.3803/EnM.2018.33.2.228
[15] Suman P, Wang CH, Abadin SS, et al.  Timing of radioactive iodine therapy doses not impact overall survival in high-risk papillary thyroid carcinoma[J]. Endocr Pract, 2016, 22(7): 822-831.   doi: 10.4158/EP151088.OR
[16] Kim M, Han M, Jeon MJ, et al.  Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2019, 91(3): 449-455.   doi: 10.1111/cen.14039
[17] Krajewska J, Jarzab M, Kukulska A, et al.  Postoperative radioiodine treatment within 9 months from diagnosis significantly reduces the risk of relapse in low-risk differentiated thyroid carcinoma[J]. Nucl Med Mol Imaging, 2019, 53(5): 320-327.   doi: 10.1007/s13139-019-00608-8
[18] Scheffel RS, Zanella AB, Dora JM, et al.  Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma[J]. Thyroid, 2016, 26(11): 1623-1629.   doi: 10.1089/thy.2016.0038
[19]

Simsek FS, Balci TA, Donder Y, et al. How important is the timing of radioiodine ablation in differentiated thyroidal carcinomas: a referral centre experience[J/OL]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2020, 39(3): 157−162[2021-03-03]. https://www.sciencedirect.com/science/article/abs/pii/S2253654X19301829?via%3Dihub. DOI: 10.1016/j.remn.2019.08.004.
[20] Higashi T, Nishii R, Yamada S, et al.  Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases[J]. J Nucl Med, 2011, 52(5): 683-689.   doi: 10.2967/jnumed.110.081059
[21] Ahn J, Jin MH, Song EY, et al.  Clinical outcomes after early and delayed radioiodine remnant ablation in patients with low-risk papillary thyroid carcinoma: propensity score matching analysis[J]. Endocrinol Metab (Seoul), 2020, 35(4): 830-837.   doi: 10.3803/EnM.2020.747
[22] Tsirona S, Vlassopoulou V, Tzanela M, et al.  Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer[J]. Clin Endocrinol (Oxf), 2014, 80(3): 459-463.   doi: 10.1111/cen.12301
[23] Li H, Zhang YQ, Wang C, et al.  Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer[J]. Clin Endocrinol (Oxf), 2018, 88(4): 601-606.   doi: 10.1111/cen.13551
[24] 刘日信, 李建芳, 曾凤伟, 等.  分化型甲状腺癌术后首次131I治疗时间选择对疗效的影响[J]. 现代肿瘤医学, 2018, 26(19): 3042-3045.   doi: 10.3969/j.issn.1672-4992.2018.19.011
Liu RX, Li JF, Zeng FW, et al.  Effect of time selection on initial 131I treatment in post-surgery patients with differentiated thyroid cancer[J]. Mod Oncol, 2018, 26(19): 3042-3045.   doi: 10.3969/j.issn.1672-4992.2018.19.011
[25] 陈鹏, 宋长祥, 陆武, 等.  首次131I治疗前监测甲状腺球蛋白预测分化型甲状腺癌转移的临床价值[J]. 中华内分泌代谢杂志, 2018, 34(2): 102-105.   doi: 10.3760/cma.j.issn.1000-6699.2018.02.003
Chen P, Song CX, Lu W, et al.  Clinical significance of tracing thyroglobulin in predicting metastasis of post-operative patients with differentiated thyroid carcinoma before its first pre-ablation with 131I[J]. Chin J Endocrinol Metab, 2018, 34(2): 102-105.   doi: 10.3760/cma.j.issn.1000-6699.2018.02.003
[26] Ben Hamida O, Sellem A, El Ajmi W, et al.  Preablative stimulated thyroglobulin in predicting dynamic risk stratification after 1 year in patients with differentiated thyroid cancer[J]. Med Nucl, 2021, 45(1): 46-49.   doi: 10.1016/j.mednuc.2020.07.003
[27] Bandeira L, Padovani RDP, Ticly AL, et al.  Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer[J]. Arch Endocrinol Metab, 2017, 61(6): 590-599.   doi: 10.1590/2359-3997000000308
[28]

Klain M, Zampella E, Piscopo L, et al. Long-term prognostic value of the response to therapy assessed by laboratory and imaging findings in patients with differentiated thyroid cancer[J/OL]. Cancers (Basel), 2021, 13(17): 4338[2022-03-03]. https://www.mdpi.com/2072-6694/13/17/4338. DOI: 10.3390/cancers13174338.
[29]

Zheng W, Rui ZY, Wang X, et al. The influences of TSH stimulation level, stimulated Tg level and Tg/TSH ratio on the therapeutic effect of 131I treatment in DTC patients[J/OL]. Front Endocrinol (Lausanne), 2021, 12: 601960[2022-03-03]. https://www.frontiersin.org/articles/10.3389/fendo.2021.601960/full. DOI: 10.3389/fendo.2021.601960.